Health-related quality of life (HR-QOL) and chronic health conditions (CHC) in survivors of childhood acute myelogenous leukemia (AML)

6590 Background: AML therapy has included chemotherapy with or without autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation (chemo±auto or alloBMT) based on the availability of a matched sibling donor. This allows unbiased comparison of HR-QOL outcomes between these groups. Methods: We surveyed 207 survivors of AML diagnosed before age 21 and treated from 1979 to 1995 on one of 4 COG protocols who survived ≥5 years from diagnosis. Survivors or proxy caregivers completed a CCSS baseline questionnaire and an age-appropriate measure of HR-QOL (SF-36, CHQ-87 or CHQ-PF50). Survivors with Down syndrome were excluded for this analysis. Results: Of the 182 survivors in this analysis, 128 underwent chemo±auto and 54 underwent alloBMT. Median age at diagnosis was 4 years (range, 0 to 20); median age at enrollment was 20 (range 8 to 39). HR-QOL scores were similar among groups and to the normative population (Physical component score: chemo±auto mean 50.8 vs. alloBMT 49.7, p=0.4...